Research chemicalPsychedelicMescaline analogueScaline
Buscaline
Also known as 4-butoxy-3,5-dimethoxyphenethylamine
Buscaline (4-butoxy-3,5-dimethoxyphenethylamine) is a butoxy scaline homologue of mescaline. Beyond the ethoxy/propoxy scalines, activity drops, and buscaline is reported as only weakly active with very sparse human data.
01 Overview
Buscaline extends the 4-alkoxy chain of the scaline series to n-butoxy. Potency in the scaline family peaks around the propoxy analogue and declines with longer chains, so buscaline is expected to be weak; the few accounts describe minimal effect at substantial doses.
It is one of the most obscure scalines, with essentially no reliable human characterisation and no toxicology.
02 Mechanism
5-HT2A partial agonist; the bulky 4-butoxy group reduces receptor potency relative to shorter-chain scalines.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Reported | 50–100 mg | Oral | Sparse reports; effect described as weak. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Weak psychedeliaFaint mescaline-like effects at high doses in limited reports. | mild | Anecdotal | |
| Mild relaxationOccasional reports of mild calm, poorly distinguished from placebo. | slight | Unconfirmed |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| NauseaOnset gastric discomfort typical of the scaline class. | Mild | Common | Anecdotal | |
| Unknown toxicityNo safety data; research-grade purity is unverifiable. | Moderate | Unknown | Unconfirmed |
06 Legal status
United Kingdom
Psychoactive Substances Act 2016
as of Jan 2026
United States
Schedule I (Federal Analogue Act)
Analogue when intended for consumption. · as of Jan 2026
07 References
PiHKAL: A Chemical Love Story (Buscaline entry)Shulgin & Shulgin, 1991
08 Discussion0 comments
Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.
This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.